Your browser doesn't support javascript.
loading
SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)
Juan Ferré, A. de; Álvarez Álvarez, R; Casado Herráez, A; Cruz Jurado, J; Estival González, A; Martín-Broto, J; Martínez Marín, V; Moreno Vega, A; Sebio García, A; Valverde Morales, C.
Affiliation
  • Juan Ferré, A. de; Hospital Universitario Marqués de Valdecilla. Santander. Spain
  • Álvarez Álvarez, R; Hospital General Universitario Gregorio Marañón. Madrid. Spain
  • Casado Herráez, A; Hospital Universitario Clínico San Carlos. Madrid. Spain
  • Cruz Jurado, J; Hospital Universitario de Canarias. Tenerife. Spain
  • Estival González, A; Institut Català d’Oncologia-Badalona. Barcelona. Spain
  • Martín-Broto, J; Hospital Universitario Virgen del Rocío. Sevilla. Spain
  • Martínez Marín, V; Hospital Universitario la Paz. Madrid. Spain
  • Moreno Vega, A; Hospital Universitario Reina Sofía. Córdoba. Spain
  • Sebio García, A; Hospital de la Santa Creu I Sant Pau. Barcelona. Spain
  • Valverde Morales, C; Hospital Universitario Vall d’Hebron. Barcelona. Spain
Clin. transl. oncol. (Print) ; 23(5): 922-930, mayo 2021. tab, ilus
Article in En | IBECS | ID: ibc-221232
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed (AU)
Subject(s)
Key words

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Sarcoma / Soft Tissue Neoplasms Limits: Humans Country/Region as subject: Europa Language: En Journal: Clin. transl. oncol. (Print) Year: 2021 Document type: Article

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Sarcoma / Soft Tissue Neoplasms Limits: Humans Country/Region as subject: Europa Language: En Journal: Clin. transl. oncol. (Print) Year: 2021 Document type: Article